7
Nov
2024
What Will Trump Do? Look at the Record
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2024
Developing a New Class of RNA Therapeutics: Leslie Williams on The Long Run
Today’s guest on The Long Run is Leslie Williams. Leslie is the co-founder and CEO of Boston-based hC Bioscience. Her company is working to develop a new class of RNA medicines directed at transfer RNAs, also known as tRNA. The gist of the idea is to make these tRNA therapies, delivered with a lipid nanoparticle, that can carry instructions to... Read More
4
Nov
2024
Lessons from the Manure Digester
My first real journalism job flashed to mind this week. It was 1998. I was a kid reporter fresh out of the University of Wisconsin. My job was to cover Dane County government for The Capital Times, the progressive newspaper in Madison. Dane County had about 400,000 people. Half lived in the beating liberal heart of the City of Madison... Read More
31
Oct
2024
Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Oct
2024
Archon Biosciences Gets $20M to Translate Nobel-Winning Science into Antibody ‘Cages’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2024
Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Oct
2024
A Life in Biotech Journalism, and Reaching New Heights for Good Causes
The folks at Nucleate, the global network for young scientific entrepreneurs, asked me a bunch of interesting questions. I was the guest on the Nucleate Podcast. This was an hourlong interview which covered some turning points in my life. I also offered some commentary on the current state of biotech. The co-hosts wrote: In this episode, Sam Kessel and Anastasia... Read More
16
Oct
2024
Cured With CRISPR, Living Life
Jimi Olaghere was cured of sickle cell disease four years ago by a CRISPR cell therapy. Last month, he summitted Kilimanjaro. This is a testament to science at its best, and the human spirit. If you and your team are looking for inspiration, watch this 35-minute interview I conducted with Jimi at The Meeting on the Mesa. Thanks to the... Read More
15
Oct
2024
Designing Protein Drugs for Cancer & Autoimmunity: Chris Garcia on The Long Run
Today’s guest on The Long Run is K. Christopher Garcia. Chris is a professor of molecular and cellular physiology and structural biology at Stanford University and an investigator for the Howard Hughes Medical Institute. To be a bit more specific, you can call him a structural immunologist – the kind of scientist who uses the vivid tools of structural biology... Read More
10
Oct
2024
Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Oct
2024
Booster Gets $15M from Apollo, Novo to Develop Proteasome Activators for Neurodegeneration
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2024
Basecamp Research Secures $60M to Hone First Principles for AI Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2024
Call for Entries: Join the Timmerman Traverse for Damon Runyon Cancer Research
Are you ready for a bucket list adventure? Join me and a team of biotech executives and investors on the Timmerman Traverse for Damon Runyon Cancer Research Foundation. It’s a trek to Everest Base Camp (17,600 feet) in April 2025. Who’s on the Team? Luke Timmerman, founder & editor, Timmerman Report (team captain) Soufiane Aboulhouda, co-founder and CEO, Nucleate Tamar... Read More
3
Oct
2024
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2024
Triveni Bio Secures $115M to Treat Immune & Inflammatory Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2024
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2024
Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run
Zach Hornby is today’s guest on The Long Run. Zach is the CEO of San Diego-based Boundless Bio. The company is seeking to target cancer cells in an unusual way. It is developing small molecule drugs that take aim at DNA that resides outside the usual home on a chromosome. These oncogene amplifications occur in loops outside the chromosome. This... Read More
17
Sep
2024
Sickle Cell Patient Cured With CRISPR Summits Kilimanjaro, Setting World Record
Four years after being functionally cured of sickle cell disease with a CRISPR gene-editing therapy, Jimi Olaghere has set a new world record for patients with this chronic and deadly disease. Olaghere, a 39-year-old business owner from Atlanta, became the world’s first patient with sickle cell disease to reach the summit of Kilimanjaro at 7:30 am Tanzania time on Sept.... Read More
10
Sep
2024
Amy Abernethy, Brad Hirsch Aim for Better Medical Evidence With Highlander Health
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2024
Candid Therapeutics Emerges with $370M to Develop T-Cell Engagers for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.